首页 | 官方网站   微博 | 高级检索  
     

钾通道参与高铁血红素诱导的心肌保护作用
引用本文:徐和靖,朱立,汪洋,沈法荣,金红峰,沈岳良,陈莹莹.钾通道参与高铁血红素诱导的心肌保护作用[J].浙江大学学报(医学版),2007,36(1):7-12.
作者姓名:徐和靖  朱立  汪洋  沈法荣  金红峰  沈岳良  陈莹莹
作者单位:1. 浙江大学医学院,生理学系,浙江,杭州,310058;温州医学院生理学教研室,浙江,温州,325027
2. 浙江大学医学院,生理学系,浙江,杭州,310058
3. 温州医学院生理学教研室,浙江,温州,325027
4. 浙江医院心内科,浙江,杭州,310013
基金项目:国家自然科学基金;浙江省自然科学基金
摘    要:目的:研究血红素氧化酶1的诱导剂高铁血红素在对抗大鼠心肌缺血-复灌损伤中的作用及其相应机制。方法:利用离体大鼠心脏Langendorff灌流模型,观察心功能、心肌梗死面积等指标的变化。结果:腹腔注射高铁血红素后24 h,可明显改善缺血-复灌心脏(30 m in缺血/2 h复灌)的收缩功能,减少复灌期乳酸脱氢酶(LDH)和肌酸磷酸(CK)的释放,缩小心肌梗死面积。在腹腔注射高铁血红素前给予线粒体KATP通道阻断剂5-HD或肌膜KATP通道阻断剂HMR-1098均可取消高铁血红素引发的心肌保护作用。在高铁血红素预处理后24 h,缺血/复灌前10 m in给予K ca通道阻断剂pax illine,与高铁血红素组相比,心肌梗死面积扩大,心脏收缩功能下降。结论:高铁血红素预处理可对抗心肌缺血-复灌性损伤,其作用可能与激活KATP通道和K ca通道有关。

关 键 词:氯化血红素/药物作用  心肌缺血/预防和控制  钾通道/药物作用  心肌再灌注  损伤/预防和控制
文章编号:1008-9292(2007)01-0007-06
收稿时间:2006-03-06
修稿时间:2006-04-17

Involvement of potassium channel in hemin-induced cardioprotection in rat hearts
XU He-jing, ZHU Li, WANG Yang, et al.Involvement of potassium channel in hemin-induced cardioprotection in rat hearts[J].Journal of Zhejiang University(Medical Sciences),2007,36(1):7-12.
Authors:XU He-jing  ZHU Li  WANG Yang  
Affiliation:Department of Physiology, College of Medicine, Zhejiang University, Hangzhou 310058, China.
Abstract:OBJECTIVE: To investigate the effects of heme oxygenase 1 inducer hemin on protection of ischemia-reperfusion injury in rats and its mechanisms. METHODS: The Langendorff model of isolated rat heart was used; the left anterior descending coronary artery was occluded for 30 min and subsequently reperfused for 2 h. Then the ventricular function and infarct size were measured. RESULT: Hemin preconditioning prevented the increase in LVEDP, decrease in LVDP and +/- dp/dt(max) in the isolated ischemia-reperfusion rat hearts. The leakage of LDH and CK in the coronary effluent was significantly declined in hemin-treated rat hearts. And the infarct size was also reduced. Administration of a blocker of mitochondrial ATP-sensitive potassium channel (mitoK(ATP)) 5-HD (5 mg/kg) before hemin preconditioning increased the LVEDP, and reduced the LVDP and +/- dp/dt(max). The leakage of LDH and CK in the coronary effluent and the infarct size were also increased compared with only hemin-treated rat hearts. Pretreatment of the rats with a blocker of sarcolemmal ATP-sensitive potassium channel (sarcK(ATP)) HMR-1098 (6 mg/kg) before hemin preconditioning also abolished the protective effect. Infusion of paxilline (1 micromol/L), a blocker of calcium activated potassium channel (K(Ca)) for 10 min before ischemia/reperfusion led to larger infarct size and poorer myocardial performance as compared with the hemin group. The leakage of LDH and CK in the coronary effluent was also increased. CONCLUSION: Both mitoK(ATP)and sarcK(ATP)channels activation are required for the delayed cardioprotection induced by hemin. The opening of K(Ca) channels-dependent mechanism may be involved in the protection.
Keywords:Hemin/drug effe  Myocardial ischemia/prev  Potassium channels/drug effe  Myocardial reperfusion injury/prev
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号